Skip to main content

Select Drug Profiles

Gilotrif (Afatinib): Second-Generation Tyrosine Kinase Inhibitor Indicated for the First-Line Treatment of Patients with Non–Small-Cell Lung Cancer and EGFR Mutation

Lisa A. Raedler, PhD, RPh

Ilaris (Canakinumab) Receives a New Indication for the Treatment of Systemic Juvenile Idiopathic Arthritis

Lisa A. Raedler, PhD, RPh

Imbruvica (Ibrutinib) for Mantle-Cell Lymphoma: First Bruton’s Tyrosine Kinase Inhibitor Approved for Use in a Hematologic Malignancy

Lisa A. Raedler, PhD, RPh

Injectafer (Ferric Carboxymaltose Injection) Receives FDA Approval for the Treatment of Iron-Deficiency Anemia

Invokana (Canagliflozin): First-in-Class SGLT2 Inhibitor Approved for the Treatment of Type 2 Diabetes

Kadcyla (Ado-Trastuzumab Emtansine): First Antibody-Drug Conjugate Approved for the Treatment of HER2-Positive Metastatic Breast Cancer

Lisa A. Raedler, PhD, RPh

Mirvaso (Brimonidine): First Topical Gel Approved by the FDA for the Treatment of Facial Erythema of Rosacea

Latuda (Lurasidone HCl) Receives 2 New Indications for Use in Bipolar Depression as Monotherapy and as Adjunctive Therapy with Lithium or Valproate

Nesina, Kazano, and Oseni: Three Alogliptin-Based Agents Approved for the Treatment of Type 2 Diabetes

Otrexup (Methotrexate) Injection: Novel Methotrexate Delivery System for Patients with Rheumatoid Arthritis

Lisa A. Raedler, PhD, RPh

Page 153 of 244
Results 1521 - 1530 of 2434